Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
60%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (40.0%)
N/A3 (60.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Physical Activity Centers Empowerment

NCT06411756
completednot_applicable

High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer

NCT02923401
completednot_applicable

C2P - Phase III: MPowerment and Community Promise

NCT00381784
completedphase_2

Intravitreal Injections-related Anxiety

NCT02035722
completedphase_2

Behavioral Study to Control Blood Pressure

NCT01035554

Clinical Trials (5)

Showing 5 of 5 trials
NCT06411756Not Applicable

Physical Activity Centers Empowerment

Completed
NCT02923401Not Applicable

High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer

Completed
NCT00381784Not Applicable

C2P - Phase III: MPowerment and Community Promise

Completed
NCT02035722Phase 2

Intravitreal Injections-related Anxiety

Completed
NCT01035554Phase 2

Behavioral Study to Control Blood Pressure

Completed

All 5 trials loaded

Drug Details

Intervention Type
BEHAVIORAL
Total Trials
5